Objective To assess the effectiveness, safety, and tolerability of erenumab in a real‐life
migraine population, while trying to identify responsiveness predictors. Background …

Objective To evaluate the long‐term effectiveness, safety, and tolerability of erenumab in a
real‐world migraine population, looking for putative predictors of responsiveness …

Background We aimed to assess the efficacy and safety of erenumab, a fully human
monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr), for the …

Background erenumab was safe and effective in clinical trials for the prevention of migraine.
However, real-life data are still lacking. Here we report the clinical experience from an Italian …

Objective EMPOwER, a double-blind, randomised, phase 3 study, evaluated the efficacy
and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and …

Background Clinical trials have shown that erenumab is effective and well-tolerated for the
preventive treatment of chronic migraine. To extend the results from clinical trials, we …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Background Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the
first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting …

Background Erenumab, a calcitonin gene‐related peptide (CGRP) receptor monoclonal
antibody, has been well tolerated with good efficacy for the preventive treatment of episodic …

Background Erenumab was approved in Europe for migraine prevention in patients with≥ 4
monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access …